05:12 PM EDT, 06/23/2025 (MT Newswires) -- Terns Pharmaceuticals ( TERN ) said that data from a phase 1 study of experimental weight loss treatment TERN-601 showed positive results.

TERN-601, a once-daily oral GLP-1 receptor agonist, is part of a class of drugs commonly used to support weight loss and blood sugar control.

The study showed that TERN-601 helped patients lose up to 5.5% of body weight over 28 days with 67% of participants on the highest dose losing at least 5%, meeting the trial's primary endpoint, the company said Monday in a statement. The effect was dose-dependent and statistically significant, Terns said.

The drug was well tolerated with no treatment-related interruptions or dropouts, while most side effects were mild, even with rapid dose increases every three days, the company said.

Terns has completed enrollment for its phase 2 trial, which will test weight loss results over 12 weeks and compare them with a placebo, expecting topline results by the end of 2025, the company said.